Do analysts prefer ICCC or IKT?

Inhibikase Therapeutics has a consensus price target of $5.40, suggesting a potential upside of 116.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Inhibikase Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.00

Does the media refer more to VNDA or ICCC?

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than ImmuCell. MarketBeat recorded 2 mentions for Vanda Pharmaceuticals and 1 mentions for ImmuCell. Vanda Pharmaceuticals' average media sentiment score of 0.84 beat ImmuCell's score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmuCell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NMRA or ICCC?

Neumora Therapeutics currently has a consensus price target of $6.57, indicating a potential upside of 330.91%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Neumora Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.60 ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer NMRA or ICCC?

In the previous week, Neumora Therapeutics had 29 more articles in the media than ImmuCell. MarketBeat recorded 30 mentions for Neumora Therapeutics and 1 mentions for ImmuCell. Neumora Therapeutics' average media sentiment score of 0.21 beat ImmuCell's score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmuCell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AMRN or ICCC?

Amarin currently has a consensus target price of $13.00, suggesting a potential downside of 6.07%. Given Amarin's higher possible upside, analysts plainly believe Amarin is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33 ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, AMRN or ICCC?

ImmuCell has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $186.23M 1.57 -$38.80M -$0.99 N/A ImmuCell $27.64M 3.23 -$1.04M $0.08 123.00

Is AMRN or ICCC more profitable?

ImmuCell has a net margin of 2.57% compared to Amarin's net margin of -14.56%. ImmuCell's return on equity of 2.69% beat Amarin's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -14.56% -0.20% -0.14% ImmuCell 2.57% 2.69% 1.76%

Does the media prefer AMRN or ICCC?

In the previous week, Amarin had 6 more articles in the media than ImmuCell. MarketBeat recorded 7 mentions for Amarin and 1 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.00 beat Amarin's score of -0.29 indicating that ImmuCell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ImmuCell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ICCC or TTRX?

Turn Therapeutics has a consensus target price of $8.00, suggesting a potential downside of 17.36%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Turn Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Turn Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media favor ICCC or TTRX?

In the previous week, Turn Therapeutics had 1 more articles in the media than ImmuCell. MarketBeat recorded 2 mentions for Turn Therapeutics and 1 mentions for ImmuCell. Turn Therapeutics' average media sentiment score of 0.34 beat ImmuCell's score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ImmuCell (ICCC) Competitors

$9.84 -0.22 (-2.19%)

Closing price 04:00 PM Eastern

Extended Trading

$9.86 +0.03 (+0.25%)

As of 04:10 PM Eastern

Compare

ICCC vs. IKT, VNDA, NMRA, AMRN, and TTRX

Should you buy ImmuCell stock or one of its competitors? ImmuCell's main competitors and comparable companies include Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), Neumora Therapeutics (NMRA), Amarin (AMRN), and Turn Therapeutics (TTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ImmuCell compare to Inhibikase Therapeutics?

ImmuCell (NASDAQ:ICCC) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Inhibikase Therapeutics has a consensus price target of $5.40, suggesting a potential upside of 116.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, ImmuCell had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 1 mentions for ImmuCell and 0 mentions for Inhibikase Therapeutics. ImmuCell's average media sentiment score of 0.00 equaled Inhibikase Therapeutics'average media sentiment score.

Company	Overall Sentiment
ImmuCell	Neutral
Inhibikase Therapeutics	Neutral

ImmuCell has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ImmuCell has a net margin of 2.57% compared to Inhibikase Therapeutics' net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

ImmuCell has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.23	-$1.04M	$0.08	123.00
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A

Summary

ImmuCell beats Inhibikase Therapeutics on 9 of the 15 factors compared between the two stocks.

How does ImmuCell compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

ImmuCell has a net margin of 2.57% compared to Vanda Pharmaceuticals' net margin of -127.41%. ImmuCell's return on equity of 2.69% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
ImmuCell	2.57%	2.69%	1.76%

Vanda Pharmaceuticals presently has a consensus target price of $13.70, indicating a potential upside of 157.04%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vanda Pharmaceuticals is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 5.7% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than ImmuCell. MarketBeat recorded 2 mentions for Vanda Pharmaceuticals and 1 mentions for ImmuCell. Vanda Pharmaceuticals' average media sentiment score of 0.84 beat ImmuCell's score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmuCell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vanda Pharmaceuticals has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

ImmuCell has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.49	-$220.47M	-$4.63	N/A
ImmuCell	$27.64M	3.23	-$1.04M	$0.08	123.00

Summary

Vanda Pharmaceuticals beats ImmuCell on 9 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

ImmuCell has a net margin of 2.57% compared to Neumora Therapeutics' net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
ImmuCell	2.57%	2.69%	1.76%

Neumora Therapeutics has a beta of 2.75, suggesting that its share price is 175% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

ImmuCell has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
ImmuCell	$27.64M	3.23	-$1.04M	$0.08	123.00

In the previous week, Neumora Therapeutics had 29 more articles in the media than ImmuCell. MarketBeat recorded 30 mentions for Neumora Therapeutics and 1 mentions for ImmuCell. Neumora Therapeutics' average media sentiment score of 0.21 beat ImmuCell's score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmuCell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 5.7% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neumora Therapeutics currently has a consensus price target of $6.57, indicating a potential upside of 330.91%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Neumora Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Neumora Therapeutics beats ImmuCell on 9 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Amarin?

Amarin (NASDAQ:AMRN) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Amarin currently has a consensus target price of $13.00, suggesting a potential downside of 6.07%. Given Amarin's higher possible upside, analysts plainly believe Amarin is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

ImmuCell has a net margin of 2.57% compared to Amarin's net margin of -14.56%. ImmuCell's return on equity of 2.69% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
ImmuCell	2.57%	2.69%	1.76%

ImmuCell has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$186.23M	1.57	-$38.80M	-$0.99	N/A
ImmuCell	$27.64M	3.23	-$1.04M	$0.08	123.00

22.3% of Amarin shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 5.7% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Amarin had 6 more articles in the media than ImmuCell. MarketBeat recorded 7 mentions for Amarin and 1 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.00 beat Amarin's score of -0.29 indicating that ImmuCell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmuCell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amarin has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Summary

ImmuCell beats Amarin on 10 of the 15 factors compared between the two stocks.

How does ImmuCell compare to Turn Therapeutics?

ImmuCell (NASDAQ:ICCC) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

ImmuCell has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.23	-$1.04M	$0.08	123.00
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

ImmuCell has a net margin of 2.57% compared to Turn Therapeutics' net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
Turn Therapeutics	N/A	-230.84%	-53.19%

In the previous week, Turn Therapeutics had 1 more articles in the media than ImmuCell. MarketBeat recorded 2 mentions for Turn Therapeutics and 1 mentions for ImmuCell. Turn Therapeutics' average media sentiment score of 0.34 beat ImmuCell's score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Turn Therapeutics has a consensus target price of $8.00, suggesting a potential downside of 17.36%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Turn Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

13.5% of ImmuCell shares are held by institutional investors. 5.7% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

ImmuCell beats Turn Therapeutics on 9 of the 15 factors compared between the two stocks.

Get ImmuCell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ICCC vs. The Competition

Export

Metric	ImmuCell	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$89.35M	$12.42B	$7.29B	$12.71B
Dividend Yield	N/A	2.62%	2.54%	10.79%
P/E Ratio	123.02	780.42	271.39	24.10
Price / Sales	3.23	789.54	604.58	77.05
Price / Cash	52.18	15.47	29.03	36.90
Price / Book	3.29	10.42	11.18	6.40
Net Income	-$1.04M	$2.79B	$3.46B	$348.28M
7 Day Performance	1.44%	2.25%	1.98%	0.92%
1 Month Performance	-10.79%	4.72%	7.32%	5.10%
1 Year Performance	61.58%	7.07%	24.76%	16.16%

ImmuCell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ICCC ImmuCell	1.057 of 5 stars	$9.84 -2.2%	N/A	+65.2%	$89.35M	$27.64M	123.02	70	High Trading Volume
IKT Inhibikase Therapeutics	1.4202 of 5 stars	$2.45 +2.1%	$5.40 +120.4%	N/A	$341.87M	$260K	N/A	6
VNDA Vanda Pharmaceuticals	3.1114 of 5 stars	$5.57 +2.4%	$13.70 +146.0%	+11.2%	$336.78M	$215.72M	N/A	290
NMRA Neumora Therapeutics	2.9125 of 5 stars	$1.64 flat	$6.57 +300.7%	+0.6%	$303.86M	N/A	N/A	108	Positive News Insider Trade
AMRN Amarin	0.8177 of 5 stars	$14.38 +1.8%	N/A	-11.8%	$303.71M	$213.65M	N/A	360	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ICCC) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmuCell (ICCC) Competitors

ICCC vs. IKT, VNDA, NMRA, AMRN, and TTRX

How does ImmuCell compare to Inhibikase Therapeutics?

Summary

How does ImmuCell compare to Vanda Pharmaceuticals?

Summary

How does ImmuCell compare to Neumora Therapeutics?

Summary

How does ImmuCell compare to Amarin?

Summary

How does ImmuCell compare to Turn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmuCell (ICCC) Competitors

ICCC vs. IKT, VNDA, NMRA, AMRN, and TTRX

How does ImmuCell compare to Inhibikase Therapeutics?

Do analysts prefer ICCC or IKT?

Does the media favor ICCC or IKT?

Which has more volatility and risk, ICCC or IKT?

Do insiders and institutionals hold more shares of ICCC or IKT?

Is ICCC or IKT more profitable?

Which has higher valuation and earnings, ICCC or IKT?

Summary

How does ImmuCell compare to Vanda Pharmaceuticals?

Is VNDA or ICCC more profitable?

Do analysts recommend VNDA or ICCC?

Do insiders & institutionals have more ownership in VNDA or ICCC?

Does the media refer more to VNDA or ICCC?

Which has more volatility and risk, VNDA or ICCC?

Which has stronger earnings and valuation, VNDA or ICCC?

Summary

How does ImmuCell compare to Neumora Therapeutics?

Is NMRA or ICCC more profitable?

Which has more risk & volatility, NMRA or ICCC?

Which has better valuation and earnings, NMRA or ICCC?

Does the media prefer NMRA or ICCC?

Do insiders and institutionals have more ownership in NMRA or ICCC?

Do analysts recommend NMRA or ICCC?

Summary

How does ImmuCell compare to Amarin?

Do analysts recommend AMRN or ICCC?

Is AMRN or ICCC more profitable?

Which has stronger earnings & valuation, AMRN or ICCC?

Do institutionals and insiders hold more shares of AMRN or ICCC?

Does the media prefer AMRN or ICCC?

Which has more volatility and risk, AMRN or ICCC?

Summary

How does ImmuCell compare to Turn Therapeutics?

Which has higher earnings and valuation, ICCC or TTRX?

Is ICCC or TTRX more profitable?

Does the media favor ICCC or TTRX?

Do analysts prefer ICCC or TTRX?

Do institutionals and insiders believe in ICCC or TTRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools